[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565569":3},{"organization":4,"armGroups":7,"interventions":41,"overallOfficials":56,"centralContacts":60,"locations":65,"responsibleParty":171,"collaborators":32,"id":173,"slug":174,"hasResults":175,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":32,"eligibilityCriteria":179,"healthyVolunteers":175,"sex":180,"minAge":181,"maxAge":32,"enrollmentInfo":182,"targetDuration":32,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":68,"whyStopped":32,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},{"fullName":5,"class":6},"Aura Biosciences","INDUSTRY",[8,16,20,24,28,33,37],{"label":9,"type":10,"description":11,"interventionNames":12},"80 micrograms of bel-sar","EXPERIMENTAL","1 Cycle AU-011 with a dose of 80 micrograms",[13,14,15],"Drug: AU-011","Device: SCS Microinjector","Device: Laser",{"label":17,"type":10,"description":18,"interventionNames":19},"140 micrograms of bel-sar","1 Cycle AU-011 with a dose of 140 micrograms",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"200 micrograms of bel-sar with one cycle","1 Cycle AU-011 with a dose of 200 micrograms",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"200 micrograms of bel-sar with two cycles","2 Cycles AU-011 with a dose of 200 micrograms",[13,14,15],{"label":29,"type":30,"description":31,"interventionNames":32},"Observational","NO_INTERVENTION","Subjects that meet trial inclusion, but do not meet criteria for enrollment into the bel-sar treatment cohorts, may be enrolled in this cohort. The observational cohort will not receive bel-sar treatment.",null,{"label":34,"type":10,"description":35,"interventionNames":36},"40 micrograms of bel-sar with one cycle","1 Cycle AU-011 with a dose of 40 micrograms",[13,14,15],{"label":38,"type":10,"description":39,"interventionNames":40},"40 micrograms of bel-sar with two cycles","2 Cycles AU-011 with a dose of 40 micrograms",[13,14,15],[42,47,52],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":32},"DRUG","AU-011","AU-011 Via Suprachoroidal Administration with laser treatment",[17,21,25,34,38,9],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":32},"DEVICE","SCS Microinjector","Suprachoroidal Injection Device",[17,21,25,34,38,9],{"type":48,"name":53,"description":54,"armGroupLabels":55,"otherNames":32},"Laser","Laser Administration",[17,21,25,34,38,9],[57],{"name":58,"affiliation":5,"role":59},"Medical Monitor","STUDY_DIRECTOR",[61],{"name":58,"role":62,"phone":63,"phoneExt":32,"email":64},"CONTACT","617-500-8864","clinical@aurabiosciences.com",[66,80,90,100,110,121,131,141,151,161],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":32},"Byers Eye Institute at Stanford University","RECRUITING","Palo Alto","California","94303","United States","US",{"type":75,"coordinates":76},"Point",[77,78],-122.14302,37.44188,{"lat":78,"lon":77},{"facility":81,"status":68,"city":82,"state":83,"zip":84,"country":72,"countryCode":73,"cosmosGeoPoint":85,"geoPoint":89,"contacts":32},"Bascom Palmer Eye Institute","Miami","Florida","33136",{"type":75,"coordinates":86},[87,88],-80.19366,25.77427,{"lat":88,"lon":87},{"facility":91,"status":68,"city":92,"state":93,"zip":94,"country":72,"countryCode":73,"cosmosGeoPoint":95,"geoPoint":99,"contacts":32},"Massachusetts Eye and Ear","Boston","Massachusetts","02114",{"type":75,"coordinates":96},[97,98],-71.05977,42.35843,{"lat":98,"lon":97},{"facility":101,"status":68,"city":102,"state":103,"zip":104,"country":72,"countryCode":73,"cosmosGeoPoint":105,"geoPoint":109,"contacts":32},"Kellogg Eye Center","Ann Arbor","Michigan","48105",{"type":75,"coordinates":106},[107,108],-83.74088,42.27756,{"lat":108,"lon":107},{"facility":111,"status":112,"city":113,"state":114,"zip":115,"country":72,"countryCode":73,"cosmosGeoPoint":116,"geoPoint":120,"contacts":32},"Mayo Clinic","NOT_YET_RECRUITING","Rochester","Minnesota","55905",{"type":75,"coordinates":117},[118,119],-92.4699,44.02163,{"lat":119,"lon":118},{"facility":122,"status":112,"city":123,"state":124,"zip":125,"country":72,"countryCode":73,"cosmosGeoPoint":126,"geoPoint":130,"contacts":32},"Cleveland Clinic, Cole Eye Institute","Cleveland","Ohio","44195",{"type":75,"coordinates":127},[128,129],-81.69541,41.4995,{"lat":129,"lon":128},{"facility":132,"status":112,"city":133,"state":134,"zip":135,"country":72,"countryCode":73,"cosmosGeoPoint":136,"geoPoint":140,"contacts":32},"Shields and Shields, PC","Philadelphia","Pennsylvania","19107",{"type":75,"coordinates":137},[138,139],-75.16362,39.95238,{"lat":139,"lon":138},{"facility":142,"status":68,"city":143,"state":144,"zip":145,"country":72,"countryCode":73,"cosmosGeoPoint":146,"geoPoint":150,"contacts":32},"Tennessee Retina, PC","Nashville","Tennessee","37203",{"type":75,"coordinates":147},[148,149],-86.78444,36.16589,{"lat":149,"lon":148},{"facility":152,"status":68,"city":153,"state":154,"zip":155,"country":72,"countryCode":73,"cosmosGeoPoint":156,"geoPoint":160,"contacts":32},"Retina Consultants of Texas","Bellaire","Texas","77401",{"type":75,"coordinates":157},[158,159],-95.45883,29.70579,{"lat":159,"lon":158},{"facility":162,"status":68,"city":163,"state":164,"zip":165,"country":72,"countryCode":73,"cosmosGeoPoint":166,"geoPoint":170,"contacts":32},"University of Washington","Seattle","Washington","98104",{"type":75,"coordinates":167},[168,169],-122.33207,47.60621,{"lat":169,"lon":168},{"type":172,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100565569","phase-2-suprachoroidal-administration-in-subjects-with-metastases-to-the-choroid-100565569",false,"NCT06643884","Suprachoroidal Administration in Subjects With Metastases to the Choroid","A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid","Inclusion Criteria:\n\n* Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.\n* Have at least one Metastases to the Choroid in the study eye\n\nExclusion Criteria:\n\n* Active ocular infection or disease.\n* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.\n* Must not be planning or expecting to switch\u002Fadd systemic antineoplastic therapies during treatment","ALL","18 Years",{"count":183,"type":184},24,"ESTIMATED","INTERVENTIONAL",[187],"PHASE2","The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.",[190,191],"Eye Cancer","Primary Cancer",[193,194,195,196],"Choroidal Metastasis","Metastases to the Choroid","ocular","eye","2026-03-11",{"date":199,"type":200},"2026-03-13","ACTUAL",{"date":202,"type":200},"2024-12-16",{"date":204,"type":184},"2027-10-31",{"name":5,"class":6},10]